Bank Of New York Mellon Corp Biomarin Pharmaceutical Inc Transaction History

Bank Of New York Mellon Corp

$528 Trillion
Q2 2024

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$87.74 - $117.27 $182 Million - $244 Million	2,079,649 New	2,079,649 $202 Billion
Q4 2022 Feb 14, 2023	BUY	$80.93 - $108.63 $138 Million - $185 Million	1,703,799 New	1,703,799 $176 Million
Q3 2022 Nov 14, 2022	SELL	$82.16 - $96.94 $16.8 Million - $19.8 Million	-204,566 Reduced 15.15%	1,145,948 $97.1 Million
Q2 2022 Aug 15, 2022	BUY	$71.48 - $86.85 $43.4 Million - $52.8 Million	607,467 Added 81.75%	1,350,514 $112 Million
Q1 2022 May 11, 2022	BUY	$74.28 - $92.69 $2.98 Million - $3.72 Million	40,159 Added 5.71%	743,047 $57.3 Million
Q4 2021 Feb 11, 2022	SELL	$71.72 - $91.47 $145,017 - $184,952	-2,022 Reduced 0.29%	702,888 $62.1 Million
Q3 2021 Nov 12, 2021	BUY	$74.77 - $85.47 $752,634 - $860,341	10,066 Added 1.45%	704,910 $54.5 Million
Q2 2021 Aug 11, 2021	SELL	$75.51 - $84.79 $1.07 Million - $1.2 Million	-14,195 Reduced 2.0%	694,844 $58 Million
Q1 2021 May 13, 2021	SELL	$74.73 - $90.69 $3.1 Million - $3.76 Million	-41,475 Reduced 5.53%	709,039 $53.5 Million
Q4 2020 Feb 09, 2021	SELL	$72.61 - $90.2 $5.44 Million - $6.76 Million	-74,897 Reduced 9.07%	750,514 $65.8 Million
Q3 2020 Nov 12, 2020	SELL	$71.87 - $131.03 $19.7 Million - $35.8 Million	-273,554 Reduced 24.89%	825,411 $62.8 Million
Q2 2020 Aug 12, 2020	BUY	$79.55 - $124.22 $27.8 Million - $43.5 Million	350,064 Added 46.74%	1,098,965 $136 Million
Q1 2020 May 06, 2020	BUY	$71.37 - $96.85 $426,578 - $578,872	5,977 Added 0.8%	748,901 $63.3 Million
Q4 2019 Feb 14, 2020	SELL	$64.27 - $86.37 $881,527 - $1.18 Million	-13,716 Reduced 1.81%	742,924 $62.8 Million
Q3 2019 Nov 07, 2019	SELL	$67.4 - $85.11 $44.5 Million - $56.2 Million	-660,366 Reduced 46.6%	756,640 $51 Million
Q2 2019 Aug 12, 2019	SELL	$80.35 - $93.9 $3.77 Million - $4.41 Million	-46,935 Reduced 3.21%	1,417,006 $121 Million
Q1 2019 May 14, 2019	SELL	$84.2 - $98.62 $3.07 Million - $3.59 Million	-36,431 Reduced 2.43%	1,463,941 $130 Million
Q4 2018 Feb 11, 2019	BUY	$80.14 - $106.07 $14 Million - $18.5 Million	174,789 Added 13.19%	1,500,372 $128 Million
Q3 2018 Nov 09, 2018	SELL	$93.92 - $105.72 $1.53 Million - $1.72 Million	-16,263 Reduced 1.21%	1,325,583 $0
Q2 2018 Aug 06, 2018	SELL	$76.01 - $99.03 $5.6 Million - $7.29 Million	-73,623 Reduced 5.2%	1,341,846 $126 Million
Q1 2018 May 15, 2018	SELL	$77.67 - $92.63 $2.88 Million - $3.43 Million	-37,023 Reduced 2.55%	1,415,469 $115 Million
Q4 2017 Feb 09, 2018	BUY	$80.76 - $95.13 $117 Million - $138 Million	1,452,492	1,452,492 $130 Million

Others Institutions Holding BMRN

# of Institutions

632

Shares Held

185M

Call Options Held

1.63M

Put Options Held

1.2M

Black Rock Inc. New York, NY

22.7M
Shares

$1.6 Billion
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

19M
Shares

$1.34 Billion
0.03% of portfolio
Primecap Management CO Pasadena, CA

18.8M
Shares

$1.33 Billion
1.14% of portfolio
Dodge & Cox San Francisco, CA

13.9M
Shares

$983 Million
0.72% of portfolio
Capital Research Global Investors Los Angeles, CA

9.69M
Shares

$684 Million
0.18% of portfolio

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.

Account